All In Biotech

Drug Trial Radar · NCT01339091

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regiment (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Last checked: Nov 19, 2026Latest source record: Jan 31, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 573 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

573

Actual

Start

Mar 2011

Primary completion

Sep 2012

Study completion Nov 2012

Sponsor

Sponsor type
Industry
First posted
Apr 20, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a suspected or proven gram-positive bacterial skin or skin structure infection.

Conditions

  • Abscess
  • Wound Infection
  • Surgical Site Infection
  • Cellulitis

Interventions

  • DalbavancinDrug

    IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8

  • Vancomycin / LinezolidDrug

    IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Early Clinical EfficacyTime frame: 48-72 hours after the initiation of study therapy

Locations

91 sites in 8 countries. Site status is shown where the registry gives one.

  • Durata Study Site

    Anaheim, California

  • Durata Study Site

    Azusa, California

  • Durata Study Site

    Bellflower, California

  • Durata Study Site

    Buena Park, California

  • Durata Study Site

    Carmel, California

  • Durata Study Site

    Chula Vista, California

  • Durata Study Site

    Covina, California

  • Durata Study Site

    Fountain Valley, California

  • Durata Study Site

    La Mesa, California

  • Durata Study Site

    Long Beach, California

  • Durata Study Site

    Los Alamitos, California

  • Durata Study Site

    Los Angeles, California

  • Durata Study Site

    Oceanside, California

  • Durata Study Site

    Palm Desert, California

  • Durata Study Site

    Pasadena, California

  • Durata Study Site

    Sacramento, California

  • Durata Study Site

    San Diego, California

  • Durata Study Site

    Santa Ana, California

  • Durata Study Site

    Sylmar, California

  • Durata Study Site

    Torrance, California

  • Durata Study Site

    Upland, California

  • Durata Study Site

    Whittier, California

  • Durata Study Site

    Miami, Florida

  • Durata Study Site

    Miami, Florida

  • Durata Study Site

    Orlando, Florida

  • Durata Study Site

    Saint Cloud, Florida

  • Durata Study Site

    Tampa, Florida

  • Durata Study Site

    Columbus, Georgia

  • Durata Study Site

    Savannah, Georgia

  • Durata Study Site

    Idaho Falls, Idaho

  • Durata Study Site

    Pocatello, Idaho

  • Durata Study Site

    Moline, Illinois

  • Durata Study Site

    Rock Island, Illinois

  • Durata Study Site

    Baton Rouge, Louisiana

  • Durata Study Site

    Lafayette, Louisiana

  • Durata Clinical Site

    New Orleans, Louisiana

  • Durata Study Site

    Opelousas, Louisiana

  • Durata Study Site

    Detroit, Michigan

  • Durata Study Site

    Minneapolis, Minnesota

  • Durata Study Site

    Las Vegas, Nevada

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.